for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Top News

Breakingviews: The trials of the $57 bln drug deal

Posted

Antony Currie and Robert Cyran discuss how Valeant's possible increased bid, the potential return of Actavis as a suitor and a looming vote deadline should finally decide Allergan's fate.

Top News

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up